Critical Review: Zevra Therapeutics (NASDAQ:ZVRA) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

Zevra Therapeutics (NASDAQ:ZVRA) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Zevra Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	52.80%	54.64%	37.84%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares Zevra Therapeutics and Eloxx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47 million	6.63	$83.23 million	$1.19	9.97
Eloxx Pharmaceuticals	$6.36 million	8.32	-$5.99 million	($1.54)	-8.51

Zevra Therapeutics has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Zevra Therapeutics and Eloxx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0	1	9	1	3.00
Eloxx Pharmaceuticals	1	1	3	2	2.86

Zevra Therapeutics presently has a consensus price target of $27.14, suggesting a potential upside of 128.74%. Eloxx Pharmaceuticals has a consensus price target of $37.33, suggesting a potential upside of 184.99%. Given Eloxx Pharmaceuticals’ higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Zevra Therapeutics.

Insider & Institutional Ownership

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Zevra Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1918.69, indicating that its share price is 191,969% less volatile than the S&P 500.

Summary

Zevra Therapeutics beats Eloxx Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins. The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds.